Cipla, India's third-largest drugmaker by sales, posted fourth-quarter profit above estimates on Tuesday and said it will ...

Cipla also allayed concerns that the US government's drug pricing executive order on pharma companies, aimed at lowering cost ...

FY25 net profit beat expectations due to higher other income and a lower tax outgo, EBITDA came in slightly below estimates because of increased R&D expenditure.

Cipla, India's No. 3 drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Cipla’s Q4FY25 revenue rose 9% year-on-year to ₹6,730 crore, while it reported profit after tax of ₹1,222 crore, up 30% from ...

Cipla's stock experienced a decline in today's session, with the price decreasing by 1.45% to Rs 1498.10. There was high ...

For the new financial year, Cipla expects its topline to see "continued growth trajectory" and the management fell short of ...

Shares of HAL, Tata Power, Eicher Motors and Jubilant Food are expected to be in the spotlight today as these companies are ...

Vohra stated that the directive appears to be primarily aimed at branded pharmaceutical products rather than generic ...

May 13 (Reuters) - Cipla (CIPL.NS), opens new tab, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday, helped by strong demand for its drugs ...

The pharmaceutical segment contributed Rs 6,503.63 crore to the quarterly revenue, reflecting an 8.5 per cent growth, while ...